4. severe renal dysfunction, i.e., creatinine clearance more than twice 
normal for age 
5. severe restrictive pulmonary disease (FVC less than 40% of predicted) 
6. severe hepatic disease (bilirubin greater than 3 mg/dl or SGPT greater 
than 500 IU) 
7. severe personality disorder or mental illness 
8. previous severe cystitis from cyclophosphamide 
9. previous total dose of an th racy dines of >450 mg/m 2 
10. severe infection that on evaluation by the Principal Investigator 
precludes ablative chemotherapy or successful transplantation 
1 1 . Previous allogeneic or autologous transplant 
12. HIV reactivity 
13. Karnofsky score <70%. 
11.0 OUTLINE OF THERAPY 
11.1 Harvest guidelines: 
Patients will enter the study at the time of bone marrow harvest. Bone 
marrow must be obtained and frozen during a complete remission. 
Transduction will be done on 66% of the harvested marrow before the cells 
are frozen and stored. At least 1 x 10 8 cells/kg must be available as untreated 
back-up and at least 3 x 10 8 nucleated cells/kg must be available for the 
marking purge. It is anticipated that patients will have their bone marrow 
harvested and then proceed directly to conditioning and transplantation. 
Criteria for marrow harvest include: 
11.1.1 Pre-harvest bone marrow aspirate and biopsy performed within 3 
weeks of harvest must demonstrate adequate cellularity (based on bone 
marrow biopsy cellularity of greater than 40%, taking into account 
sampling error), and no evidence of leukemia (<5% blasts and 
absence of leukemic markers, such as Auer rods). 
[252] 
Recombinant DNA Research, Volume 17 
